Hori­zon claims mid-stage vic­to­ry in rare dis­ease, lines up PhI­II for new own­ers at Am­gen

As Hori­zon ties up the loose ends for its $28 bil­lion sale to Am­gen, a drug it picked up from a pre­vi­ous ac­qui­si­tion of its own is de­liv­er­ing a mid-stage win.

Hori­zon had al­ready de­clared Phase II suc­cess for da­zo­dal­ibep among one group of pa­tients with Sjö­gren’s syn­drome back in Sep­tem­ber. Now, it is an­nounc­ing that the drug al­so met the pri­ma­ry end­point for the sec­ond pa­tient pop­u­la­tion in the tri­al, set­ting up a 2023 launch for a Phase III pro­gram it will work with the FDA to de­sign. That time­line is ahead of ex­pec­ta­tions, the com­pa­ny added.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.